UnitedHealthcare initially denied coverage for Novartis’ drug Zolgensma, a one-time treatment for spinal muscular atrophy, but has since approved coverage for all six requests it received for the new drug.
The advanced gene treatment was approved by the FDA in May for most children under age 2 with spinal muscular atrophy. Insurers have been reluctant to cover new gene treatments based on medical necessity.
UnitedHealth Group’s CMO, Richard Migliori, MD, told The Washington Post the coverage reversals were based on clinical evidence, not on public attention generated by the denials.
Read more here.
More articles on payers:
UnitedHealth records $3.3B profit in Q2
Minnesota hospitals ask state to investigate BCBS over new policy ending coverage for 7 forms of routine care
New York insurer opens office in hospital
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
